DNA flow cytometry in sperm cells from testicular cancer patients. Impact of different treatment modalities on spermatogenesis.
In 77 patients with testicular cancer, sperm cell density was evaluated before and after treatment together with the following parameters as recorded by DNA flow cytometry: the percentage of condensed and non-condensed haploid sperm cells, and the number of non-haploid cells. The patients received either abdominal radiotherapy, cisplatin-based combination chemotherapy (+/- surgery) or did not undergo antiproliferative treatment at all. Ejaculates with a low sperm cell density had high numbers of non-condensed haploid and non-haploid cells, whereas the percentage of condensed haploid cells was decreased. However, even 'azoospermic' semen samples (by light microscopy) contained haploid cells indicating ongoing sperm cell production. One year after radiotherapy there was a significant decrease in the sperm cell density and the number of condensed haploid cells. Chemotherapy led to a significant reduction of sperm cell density evaluated 1 year after treatment. Three years after the diagnosis of testicular cancer, sperm cell production had recovered in most patients. In patients who did not have radiotherapy or chemotherapy the median density of sperm cells 3 years after treatment significantly exceeded the corresponding figure from the pretreatment situation. A low pretreatment percentage of condensed haploid cells (less than or equal to 90%) was correlated with the lack of 1-year recovery of sperm cell production. It is too early to state whether longitudinal flow cytometric data from ejaculates in testicular cancer patients yield clinically valuable information, in addition to that obtained by light microscopy. From this preliminary observation it seems that DNA flow cytometry in ejaculates from testicular cancer patients may give valuable clinical information about sperm cell production following treatment.
Fosså
S D
SD
Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
Melvik
J E
JE
Juul
N O
NO
Pettersen
E O
EO
Amellem
O
O
Theodorsen
L
L
D000970:Antineoplastic Agents / Q000009:adverse effects; D004273:DNA, Neoplasm / Q000032:analysis*; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D008297:Male; D008853:Microscopy; D011003:Ploidies; D011878:Radiotherapy / Q000009:adverse effects; D013076:Sperm Count; D013091:Spermatogenesis / Q000187:drug effects* / Q000528:radiation effects*; D013736:Testicular Neoplasms / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy*; D013997:Time Factors
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm